A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 428 participants.

Also called NCT06173570

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 428 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06173570
  • EU CT 2023-506197-12-00
Other papers using this trial's data
  • An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial Journal of the American College of Cardiology, 2025-06-03 DOI, PubMed 40167413

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Denmark, Hungary, Japan, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06173570. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-19 (actual); primary completion 2024-09-30 (actual). Results posted on 2025-11-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
Acronym
PURSUIT
Condition
Dyslipidemia
Intervention (Drug)
AZD0780
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06173570
Content hash
34a62c759bc22686565fad3bb0cfd942c1a290c5d08a2d68cc121e72b5e3a35f